These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 25028663)
1. Hepatocellular carcinoma: carcinogenesis, establishment, progression, and therapies. Guan YS; Ahmad Al-Shatouri M; He Q; Liu WM Biomed Res Int; 2014; 2014():706142. PubMed ID: 25028663 [No Abstract] [Full Text] [Related]
2. Role of stem cells in normal liver and cancer. Lau CK; Yang ZF; Fan ST Anticancer Agents Med Chem; 2011 Jul; 11(6):522-8. PubMed ID: 21554200 [TBL] [Abstract][Full Text] [Related]
3. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. Wang H; Lu Z; Zhao X J Hematol Oncol; 2019 Dec; 12(1):133. PubMed ID: 31815633 [TBL] [Abstract][Full Text] [Related]
8. The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action. Shi X; Zhu HR; Liu TT; Shen XZ; Zhu JM Cancer Lett; 2017 Aug; 400():175-182. PubMed ID: 28461246 [TBL] [Abstract][Full Text] [Related]
9. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Gailhouste L; Ochiya T Histol Histopathol; 2013 Apr; 28(4):437-51. PubMed ID: 23224781 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow cells: the source of hepatocellular carcinoma? Wu XZ; Yu XH Med Hypotheses; 2007; 69(1):36-42. PubMed ID: 17300877 [TBL] [Abstract][Full Text] [Related]
11. [Relationship between abnormal expression of heat shock protein 90 and malignant transformation of hepatocytes]. Su XQ; Yao DF Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):314-7. PubMed ID: 16635315 [No Abstract] [Full Text] [Related]
12. Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Tahmasebi Birgani M; Carloni V Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216578 [TBL] [Abstract][Full Text] [Related]
14. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Pogribny IP; Rusyn I Cancer Lett; 2014 Jan; 342(2):223-30. PubMed ID: 22306342 [TBL] [Abstract][Full Text] [Related]
15. Autophagic flux, supported by toll-like receptor 2 activity, defends against the carcinogenesis of hepatocellular carcinoma. Lin H; Hua F; Hu ZW Autophagy; 2012 Dec; 8(12):1859-61. PubMed ID: 22996042 [TBL] [Abstract][Full Text] [Related]
17. Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. Cokakli M; Erdal E; Nart D; Yilmaz F; Sagol O; Kilic M; Karademir S; Atabey N BMC Cancer; 2009 Feb; 9():65. PubMed ID: 19239691 [TBL] [Abstract][Full Text] [Related]
18. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. Zheng Y; Zhu M; Li M J Cancer Res Clin Oncol; 2020 Oct; 146(10):2439-2446. PubMed ID: 32725355 [TBL] [Abstract][Full Text] [Related]
19. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma. Xie YX; Liao R; Pan L; Du CY Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554 [TBL] [Abstract][Full Text] [Related]
20. PGE Zang S; Ma X; Wu Y; Liu W; Cheng H; Li J; Liu J; Huang A Hum Pathol; 2017 May; 63():120-127. PubMed ID: 28300577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]